Cellectis Cut to Underweight From Overweight by Barclays
Barclays downgraded Cellectis to underweight from overweight and cut its price target to $1.30 from $9.00, according to Benzinga.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.